The German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) supports the formation of a scientific network on ‘Strategies for therapeutic targeting of the Aldosterone-Mineralocorticoid Receptor signaling pathway’ (Speaker: Achim Lother). The network will bring together 20 researchers from 6 European countries covering more…
Mineralocorticoid receptor antagonists (MRAs) are highly effective therapies for cardiovascular and renal disease. However, the widespread clinical use of currently available MRAs in cardiorenal medicine is hampered by an increased risk of hyperkalemia. The mineralocorticoid receptor (MR) is a nuclear more…
Pulmonary hypertension (PH) is characterized by pulmonary vascular remodelling, leading to progressive increase in pulmonary artery pressure and subsequent right ventricular failure. Aldosterone and the mineralocorticoid receptor (MR) are key drivers of cardiovascular disease and MR antagonists are well-established in more…
